302 related articles for article (PubMed ID: 21524248)
1. Emerging anabolic treatments in osteoporosis.
Mosekilde L; Tørring O; Rejnmark L
Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
[TBL] [Abstract][Full Text] [Related]
2. Potential new drug targets for osteoporosis.
Deal C
Nat Clin Pract Rheumatol; 2009 Jan; 5(1):20-7. PubMed ID: 19098925
[TBL] [Abstract][Full Text] [Related]
3. Investigational anabolic therapies for osteoporosis.
Trivedi R; Goswami R; Chattopadhyay N
Expert Opin Investig Drugs; 2010 Aug; 19(8):995-1005. PubMed ID: 20629616
[TBL] [Abstract][Full Text] [Related]
4. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis.
Toulis KA; Anastasilakis AD; Polyzos SA; Makras P
Hormones (Athens); 2011; 10(3):174-95. PubMed ID: 22001129
[TBL] [Abstract][Full Text] [Related]
5. The use of PTH in the treatment of osteoporosis.
Borba VZ; Mañas NC
Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
[TBL] [Abstract][Full Text] [Related]
6. Combination anabolic and antiresorptive therapy for osteoporosis.
Cusano NE; Bilezikian JP
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic targets for osteoporosis: beyond denosumab.
Lim V; Clarke BL
Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
[TBL] [Abstract][Full Text] [Related]
8. The calcium-sensing receptor in bone metabolism: from bench to bedside and back.
Cianferotti L; Gomes AR; Fabbri S; Tanini A; Brandi ML
Osteoporos Int; 2015 Aug; 26(8):2055-71. PubMed ID: 26100412
[TBL] [Abstract][Full Text] [Related]
9. Abaloparatide and the Spine: A Narrative Review.
Thompson JC; Wanderman N; Anderson PA; Freedman BA
Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone as an anabolic skeletal therapy.
Rubin MR; Bilezikian JP
Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
[TBL] [Abstract][Full Text] [Related]
11. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
Bilezikian JP; Rubin MR
Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
[TBL] [Abstract][Full Text] [Related]
12. Osteoanabolic and dual action drugs.
Tabacco G; Bilezikian JP
Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
[TBL] [Abstract][Full Text] [Related]
13. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
Bhattacharyya S; Pal S; Chattopadhyay N
Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
[TBL] [Abstract][Full Text] [Related]
14. The future of osteoporosis treatment - a research update.
Lippuner K
Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185
[TBL] [Abstract][Full Text] [Related]
15. PTH (1-34): a novel anabolic drug for the treatment of osteoporosis.
Holick MF
South Med J; 2005 Nov; 98(11):1114-7. PubMed ID: 16353381
[TBL] [Abstract][Full Text] [Related]
16. Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?
Girotra M; Rubin MR; Bilezikian JP
Treat Endocrinol; 2006; 5(6):347-58. PubMed ID: 17107220
[TBL] [Abstract][Full Text] [Related]
17. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
Chew CK; Clarke BL
Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
[TBL] [Abstract][Full Text] [Related]
18. Future therapeutic targets in osteoporosis.
Deal C
Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
[TBL] [Abstract][Full Text] [Related]
19. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
20. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Cosman F; Nieves JW; Dempster DW
J Bone Miner Res; 2017 Feb; 32(2):198-202. PubMed ID: 27925287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
